KPTI - Cancer Research Highlight: Genmab Continues To Storm Into Frontline Myeloma
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage.
Genmab (GNMSF) and their partner Janssen (of Johnson & Johnson (JNJ)) have made big waves in the management of multiple myeloma, a form of blood cancer that has become one of the most dynamic niches in all of oncology. For roughly a decade now, the management of myeloma has been